| Amgen's Sensipar/Mimpara fails to meet endpoint in CV events for dialysis patients - The Pharma Letter |
|
|
Keywords: Amgen, Sensipar, Mimpara, Cardiovascular events, Dialysis patients, Ph III Article | 11 June 2012 Amgen (Nasdaq: AMGN), the world’s largest independent biotech company, announced top-line results on Friday of the Phase III ... Enjoying this article? To continue reading you need to login, take a FREE trial or subscribe. |